HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents

Risks, benefits must be balanced when choosing optimal therapy for node-negative, HER-2–positive breast cancer

Andrew D. Seidman, MD

Practice patterns, not patients, may drive overutilization in oncology

Lisa Hicks, MD, MSc

Researchers call for improved, unified national pediatric health policy

Cover Story

ONS: Successful early integration of palliative care requires multidisciplinary approach


Palliative medicine under the microscope: Not every patient with cancer needs palliative care

Derek Raghavan, MD, PhD

FDA approvals

FDA approves Farydak for multiple myeloma

FDA News

FDA expands approval of Revlimid for newly diagnosed multiple myeloma

FDA approves Lenvima for progressive differentiated thyroid cancer

FDA grants orphan drug designation to VS-5584 for mesothelioma

FDA grants breakthrough therapy designation to Rintega for EGFRvIII-positive glioblastoma

FDA grants orphan drug status to BXQ-350 for treatment of glioblastoma multiforme

FDA grants orphan drug designation to Reolysin for pancreatic cancer

FDA grants priority review to cobimetinib combined with Zelboraf for advanced melanoma

FDA advisory committees to review T-VEC for metastatic melanoma treatment

In the Journals

Paclitaxel, trastuzumab conferred low recurrence risk in HER-2-positive breast cancer

Many older patients with early-stage breast cancer receive radiation despite limited effectiveness

Patients with lymphoma can achieve long-term survival regardless of HIV status

Researchers identify approaches to manage anticoagulant-related intracerebral hemorrhage

Most women with breast cancer demonstrate ‘lack of understanding’ about disease

Medicaid reimbursements under ACA improved appointment availability

Older donor age, nonlocal distribution potentially increase HCC recurrence after liver transplant

Odds of major bleeding, mortality lower with fondaparinux than heparin

Presence of emphysema on CT scans increases lung cancer risk

Prolonged sedentary time associated with chronic disease risks

Posttransplant minimal residual disease may predict relapse for childhood ALL

Ruxolitinib superior to standard therapy for polycythemia vera

PET scans improve response assessment in peripheral T-cell lymphoma

Surgical resection effective in stage I limited-disease small cell lung cancer

Radiation plus hormone therapy benefited older men with prostate cancer

Recursive partitioning analysis forms new stages for HPV-related oropharyngeal cancer

Tamoxifen reduces density, improves survival in ER-positive breast cancer

Everolimus plus letrozole effective in recurrent endometrial carcinoma

Donor leukocyte telomere length linked to transplantation outcomes in aplastic anemia

Frailty score helps predict risk for mortality, toxicity in elderly myeloma

Active surveillance safe for favorable-risk prostate cancer

Costly therapies for hematologic malignancies provide 'reasonable value'

Bipolar androgen therapy benefited men with prostate cancer and no symptoms

Bevacizumab does not hinder quality of life for women with advanced cervical cancer

Cetuximab plus FOLFIRI only effective in RAS wild-type metastatic colorectal cancer

Thyroid cancer incidence increases in all races, ethnicities

Lung-RADS may reduce false-positives in lung cancer screening

Integrated health care may eliminate racial disparities in colon cancer survival

First-line afatinib extended OS in exon 19 deletion-positive lung adenocarcinoma

Major bleeding rates for rivaroxaban similar in real-world, clinical trial settings

Increased coffee intake reduced risk for HCC, death from chronic liver disease in multiple ethnicities

Genomic profiling provides actionable information for carcinomas of unknown primary site

Frequency of patient demands for unnecessary oncology tests overstated

Thyroid Cancer Care Collaborative offers paradigm to improve disease management, research

Half of US teenage girls fail to receive HPV vaccine at recommended age

Industry News

MD Anderson researcher receives scientific award

Institution Notes

Roswell Park Cancer Institute names new president, CEO

University of Michigan cancer center appoints director

Center names chief of neuro-oncology

AACR names 11 academy fellows

Meeting News Coverage

Testicular cancer may elevate risk for intermediate- or high-risk prostate cancer

Incidence of higher-risk prostate cancer has increased since 2011

AR-V7 status not associated with taxane chemotherapy resistance in advanced prostate cancer

Potential HCC drug stabilized disease progression

Pembrolizumab appears safe, effective in advanced gastric cancer

Risk for cancer elevated in stroke survivors